Structured Review

Cayman Chemical sars cov
<t>SARS-CoV-2</t> structural proteins.
Sars Cov, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov/product/Cayman Chemical
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
sars cov - by Bioz Stars, 2023-02
94/100 stars

Images

1) Product Images from "Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples"

Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

Journal: The Journal of General Virology

doi: 10.1099/jgv.0.001692

SARS-CoV-2 structural proteins.
Figure Legend Snippet: SARS-CoV-2 structural proteins.

Techniques Used:

Serum levels of specific antibodies targeting SARS-CoV-2 structural proteins: nucleocapsid protein ( n ), spike protein domain S1 ( s1 ) and envelope protein ( e ). Human sera were collected from three groups of patients: SARS-CoV-2, patients after confirmed SARS-CoV-2 infection; Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; Historical, serum samples collected from healthy volunteers in the years 2010–2017. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads; *, ** and ***, difference between SARS-CoV-2 and Healthy statistically significant in non-parametric ANOVA and Kruskal–Wallis test ( P <0.05, P <0.01 and P <0.001, respectively). Specific numerical values of median, mean, quartiles cutoffs, minimal, maximum and N values for each bar are given in Table S2.
Figure Legend Snippet: Serum levels of specific antibodies targeting SARS-CoV-2 structural proteins: nucleocapsid protein ( n ), spike protein domain S1 ( s1 ) and envelope protein ( e ). Human sera were collected from three groups of patients: SARS-CoV-2, patients after confirmed SARS-CoV-2 infection; Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; Historical, serum samples collected from healthy volunteers in the years 2010–2017. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads; *, ** and ***, difference between SARS-CoV-2 and Healthy statistically significant in non-parametric ANOVA and Kruskal–Wallis test ( P <0.05, P <0.01 and P <0.001, respectively). Specific numerical values of median, mean, quartiles cutoffs, minimal, maximum and N values for each bar are given in Table S2.

Techniques Used: Infection, Enzyme-linked Immunosorbent Assay

Correlations between serum levels of specific antibodies targeting SARS-CoV-2 structural proteins N, S1 and E in (a) SARS-CoV-2- patients with confirmed SARS-CoV-2 infection; ( b ) Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; ( c ) Historical, serum samples collected from healthy volunteers in the years 2010–2017. Normalized ELISA units are compared, P -values calculated by Pearson correlation are presented. Red, strong correlation; blue, weak correlation. Linear regression was used.
Figure Legend Snippet: Correlations between serum levels of specific antibodies targeting SARS-CoV-2 structural proteins N, S1 and E in (a) SARS-CoV-2- patients with confirmed SARS-CoV-2 infection; ( b ) Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; ( c ) Historical, serum samples collected from healthy volunteers in the years 2010–2017. Normalized ELISA units are compared, P -values calculated by Pearson correlation are presented. Red, strong correlation; blue, weak correlation. Linear regression was used.

Techniques Used: Infection, Enzyme-linked Immunosorbent Assay

Medical conditions correlating with the induction of antibodies targeting SARS-CoV-2 structural proteins in patients after confirmed infection with SARS-CoV-2. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads. Statistical analysis by non-parametric ANOVA and Kruskal–Wallis test ( a ) or by Mann–Whitney U test ( b, c, d ). (a) Severity of COVID-19 correlated to increased protein-specific antibody production. Patients were assigned to the groups by the physicians, with regard to symptoms, required treatment procedures, and length of the disease. (b) Rise of body temperature during infection over 38 °C was a predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) body temperature over 38 °C. (c) Breathing difficulties during infection was an inadequate predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) breathing difficulties. (d) Cough during infection as a positive predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) cough in patients.
Figure Legend Snippet: Medical conditions correlating with the induction of antibodies targeting SARS-CoV-2 structural proteins in patients after confirmed infection with SARS-CoV-2. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads. Statistical analysis by non-parametric ANOVA and Kruskal–Wallis test ( a ) or by Mann–Whitney U test ( b, c, d ). (a) Severity of COVID-19 correlated to increased protein-specific antibody production. Patients were assigned to the groups by the physicians, with regard to symptoms, required treatment procedures, and length of the disease. (b) Rise of body temperature during infection over 38 °C was a predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) body temperature over 38 °C. (c) Breathing difficulties during infection was an inadequate predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) breathing difficulties. (d) Cough during infection as a positive predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) cough in patients.

Techniques Used: Infection, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Nucleocapsid ( n ) and spike protein domain ( s1 )-specific IgG antibodies in SARS-CoV-2-infected patients in time. Serum samples were collected from SARS-CoV-2-infected patients available for multiple sampling and time points were fitted to patients’ availability. Sera were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Individual values for each patient and time point are presented. Patients are identified by numbers in accordance with Table S1. Time points are presented as approximate weeks after infection. The shaded areas represent the 95 % confidence level interval for predictions from a linear model.
Figure Legend Snippet: Nucleocapsid ( n ) and spike protein domain ( s1 )-specific IgG antibodies in SARS-CoV-2-infected patients in time. Serum samples were collected from SARS-CoV-2-infected patients available for multiple sampling and time points were fitted to patients’ availability. Sera were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. ). Individual values for each patient and time point are presented. Patients are identified by numbers in accordance with Table S1. Time points are presented as approximate weeks after infection. The shaded areas represent the 95 % confidence level interval for predictions from a linear model.

Techniques Used: Infection, Sampling, Enzyme-linked Immunosorbent Assay


Structured Review

Cayman Chemical sars cov
Indicated catechin derivatives were subjected to a neutralizing assay using a <t>SARS-CoV-2</t> Neutralizing Antibody Detection ELISA Kit (Cayman Chemical) as described in the Materials and Methods. %Inhibition for each sample is shown. Values are means ± S.D. (N=3 or 4). **P<0.01 vs. Negative control.
Sars Cov, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov/product/Cayman Chemical
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
sars cov - by Bioz Stars, 2023-02
94/100 stars

Images

1) Product Images from "Significant inactivation of SARS-CoV-2 by a green tea catechin, a catechin-derivative and galloylated theaflavins in vitro"

Article Title: Significant inactivation of SARS-CoV-2 by a green tea catechin, a catechin-derivative and galloylated theaflavins in vitro

Journal: bioRxiv

doi: 10.1101/2020.12.04.412098

Indicated catechin derivatives were subjected to a neutralizing assay using a SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (Cayman Chemical) as described in the Materials and Methods. %Inhibition for each sample is shown. Values are means ± S.D. (N=3 or 4). **P<0.01 vs. Negative control.
Figure Legend Snippet: Indicated catechin derivatives were subjected to a neutralizing assay using a SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (Cayman Chemical) as described in the Materials and Methods. %Inhibition for each sample is shown. Values are means ± S.D. (N=3 or 4). **P<0.01 vs. Negative control.

Techniques Used: Neutralizing Assay, Enzyme-linked Immunosorbent Assay, Inhibition, Negative Control